Citadel Advisors
ORMP icon

Citadel Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Citadel Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200
Closed -$428 – 14361
2025
Q1 		$428 Sell
200
-3,300
-94% -$7.61K ﹤0.01% 14264
2024
Q4 		$8.47K Buy
3,500
+1,400
+67% +$3.33K ﹤0.01% 13683
2024
Q3 		$5.12K Buy
+2,100
New +$5.12K ﹤0.01% 13517
2024
Q2 		– Sell
-2,700
Closed -$7.88K – 15072
2024
Q1 		$7.88K Sell
2,700
-600
-18% -$1.68K ﹤0.01% 13588
2023
Q4 		$7.62K Sell
3,300
-3,500
-51% -$7.48K ﹤0.01% 13276
2023
Q3 		$17.7K Buy
6,800
+2,500
+58% +$7.87K ﹤0.01% 12706
2023
Q2 		$15.4K Sell
4,300
-16,400
-79% -$52.6K ﹤0.01% 12949
2023
Q1 		$45.1K Sell
20,700
-71,000
-77% -$226K ﹤0.01% 12294
2022
Q4 		$1.1M Buy
+91,700
New +$713K ﹤0.01% 6627
2022
Q2 		– Sell
-12,600
Closed -$109K – 13762
2022
Q1 		$109K Sell
12,600
-23,600
-65% -$242K ﹤0.01% 12199
2021
Q4 		$517K Buy
36,200
+1,900
+6% +$39.7K ﹤0.01% 9616
2021
Q3 		$754K Buy
34,300
+14,600
+74% +$249K ﹤0.01% 8860
2021
Q2 		$264K Sell
19,700
-14,700
-43% -$168K ﹤0.01% 11581
2021
Q1 		$350K Buy
34,400
+19,100
+125% +$157K ﹤0.01% 10488
2020
Q4 		$65K Buy
+15,300
New +$49.8K ﹤0.01% 10462
2015
Q1 		– Sell
-1,000
Closed -$5K – 8756
2014
Q4 		$5K Sell
1,000
-1,500
-60% -$9.87K ﹤0.01% 8271
2014
Q3 		$20K Buy
+2,500
New +$22.2K ﹤0.01% 7417

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's ORMP Position: Q1 2026 in Review

Citadel Advisors reduced its Oramed Pharmaceuticals (ORMP) stake by 50% in Q1 2026, selling an estimated $330K and leaving 98,629 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #10221.

Citadel Advisors first reported a position in ORMP in Q4 2014 and has held it in 21 quarters since. The position peaked at $7.63M in Q4 2021. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Citadel Advisors held 98,629 shares of Oramed Pharmaceuticals worth $335K as of Q1 2026.
  • Citadel Advisors sold 97,391 Oramed Pharmaceuticals shares in Q1 2026, an estimated $330K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10221 holding.
  • Citadel Advisors first reported a position in Oramed Pharmaceuticals in Q4 2014 and has held it in 21 quarters since.
  • Citadel Advisors's Oramed Pharmaceuticals position peaked at $7.63M in Q4 2021.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.